In a patient with rheumatoid arthritis on methotrexate, hydroxychloroquine, and sulfasalazine who presents with fever of unknown origin, thrombocytopenia, and a splenic infarct, what are the differential diagnoses?

Differential Diagnosis for RA Patient on Triple Therapy with PUO, Thrombocytopenia, and Splenic Infarct

The most critical differential diagnoses to consider are: (1) drug-induced hemophagocytic lymphohistiocytosis (HLH), (2) methotrexate/sulfasalazine toxicity with secondary infection, (3) antiphospholipid syndrome, and (4) adult-onset Still's disease flare, with drug-induced HLH being the most immediately life-threatening and requiring urgent evaluation.

Primary Considerations

1. Drug-Induced Hemophagocytic Lymphohistiocytosis (HLH)

This is your most urgent concern given the constellation of fever, thrombocytopenia, and splenomegaly in a patient on immunosuppression 1, 2. The combination of MTX and sulfasalazine specifically increases this risk:

• Key diagnostic features to assess immediately:

  • Serum ferritin level (expect markedly elevated >500 ng/mL, often >10,000 ng/mL)
  • Triglycerides and fibrinogen levels
  • Bone marrow aspirate for hemophagocytosis
  • NK cell activity and soluble IL-2 receptor if available

• HLH can be triggered by E. coli septicemia or other infections in patients on MTX and sulfasalazine 2. The splenic infarct may represent thrombotic complications from the hyperinflammatory state.

• Critical pitfall: HLH mimics drug toxicity, making diagnosis challenging 1. Don't assume this is simply MTX toxicity without ruling out HLH.

2. Methotrexate Toxicity with Secondary Infection

MTX causes bone marrow suppression, particularly when combined with NSAIDs or in the setting of renal impairment 3, 4:

• Assess for:

  • Renal function (creatinine clearance, not just serum creatinine in elderly)
  • Folate levels
  • Recent NSAID use or timing relative to MTX dosing
  • Signs of mucositis, hepatotoxicity (transaminases, bilirubin)
  • Complete blood count showing pancytopenia vs isolated thrombocytopenia

• The FDA label explicitly warns about serious infections including fatal sepsis and pneumonia associated with myelosuppression 5, 3.

• Management decision point: If pancytopenia is present with fever, this represents a medical emergency requiring immediate broad-spectrum antibiotics and MTX discontinuation 3.

3. Sulfasalazine Hypersensitivity Syndrome

The "three-week syndrome" can occur but typically presents earlier in therapy 6:

• Look for:

  • Timing of sulfasalazine initiation (typically 3 weeks)
  • Rash, eosinophilia, hepatitis
  • Lymphocytosis
  • Internal organ involvement including hematologic abnormalities 5

• The FDA label warns of hypersensitivity reactions with internal organ involvement and hematological abnormalities 5.

4. Antiphospholipid Syndrome (APS)

Splenic infarction strongly suggests thrombotic etiology 7:

• Essential workup:

  • Anticardiolipin antibodies (IgG and IgM)
  • Anti-β2 glycoprotein I antibodies
  • Lupus anticoagulant
  • Consider overlap with SLE (ANA, anti-dsDNA, complement levels)

• Splenic infarction in a young patient with cytopenias and fever led to SLE/APS diagnosis in a recent case 7. While your patient has RA, overlap syndromes occur.

5. Adult-Onset Still's Disease (AOSD) Flare

Less likely given established RA diagnosis, but consider if:

• Double quotidian fever pattern (two fever spikes daily returning to baseline) 8
• Markedly elevated ferritin (>1000 ng/mL, often >3000 ng/mL) 8
• Evanescent salmon-colored rash
• New polyarticular arthritis pattern

Immediate Diagnostic Algorithm

Step 1: Draw stat labs:

• CBC with differential, comprehensive metabolic panel
• Ferritin, triglycerides, fibrinogen
• Blood cultures × 2
• APS panel (anticardiolipin, anti-β2GP1, lupus anticoagulant)
• Folate level

Step 2: Risk stratify based on ferritin:

• Ferritin >10,000 ng/mL → HLH until proven otherwise
• Ferritin 500-10,000 ng/mL with fever + cytopenias → pursue HLH workup
• Normal/mildly elevated ferritin → focus on drug toxicity and infection

Step 3: Assess infection risk:

• If neutropenic (ANC <1000) or febrile with any cytopenia → start empiric broad-spectrum antibiotics immediately 3
• Perform complete infectious workup including imaging for occult infection

Step 4: Medication management:

• Hold MTX and sulfasalazine immediately while awaiting workup 5, 3
• Start folinic acid rescue if MTX toxicity suspected
• Do NOT restart these medications until HLH is excluded

Step 5: Bone marrow evaluation if diagnosis unclear after initial workup

Critical Management Points

• The combination of MTX + sulfasalazine increases hematologic toxicity risk beyond either agent alone 2, 9
• Thrombocytopenia from MTX often results from drug interactions, particularly same-day dosing with NSAIDs 4
• Splenic infarction signals serious systemic disease requiring hospitalization and extensive evaluation 7
• If HLH is confirmed, cytokine release can paradoxically worsen RA activity 2

Prognosis and Follow-up

If this represents drug toxicity without HLH, MTX can often be safely reintroduced at lower doses after recovery, but sulfasalazine should be permanently discontinued if hypersensitivity is confirmed 2, 6. However, if HLH is diagnosed, mortality risk is significant and requires aggressive immunosuppressive therapy beyond simple drug withdrawal.